MCS110 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pigmented Villonodular Synovitis
Conditions
Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Trial Timeline
Apr 23, 2012 → Dec 21, 2018
NCT ID
NCT01643850About MCS110 + Placebo
MCS110 + Placebo is a phase 2 stage product being developed by Novartis for Pigmented Villonodular Synovitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01643850. Target conditions include Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath.
What happened to similar drugs?
0 of 1 similar drugs in Pigmented Villonodular Synovitis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01643850 | Phase 2 | Completed |
Competing Products
2 competing products in Pigmented Villonodular Synovitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib + Placebo | Daiichi Sankyo | Phase 3 | 40 |
| nilotinib | Novartis | Phase 2 | 35 |